Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00370552 · ClinicalTrials.gov registry record · Phase 2
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
A Phase 2 study, sponsored by R-Pharm.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT00370552: Completed Phase 2 study, sponsored by R-Pharm.
NCT00370552 is a Phase 2 study that has completed, run by R-Pharm. The registered enrollment target is 136 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00370552, a Phase 2 study, has completed, sponsored by R-Pharm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn if ixabepilone plus bevacizumab is effective in shrinking or stopping the growth of cancer when given as first-line chemotherapy in participants with metastatic breast cancer. The study will also assess the safety of this combination treatment.
Primary Outcome
CR=Disappearance of all clinical and radiologic evidence of target lesions; PR=At least 30% reduction in the sum of the longest diameter of all target lesions.
Interventions
- DRUG Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg
- DRUG Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg
- DRUG Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
What the finished NCT00370552 record still lists
NCT00370552 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg is the first listed.
NCT00370552 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00370552 about?
NCT00370552 is a clinical study titled "A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer". The purpose of this clinical research study is to learn if ixabepilone plus bevacizumab is effective in shrinking or stopping the growth of cancer when given as first-line chemotherapy in participants with metastatic breast cancer. The study will also assess the safety of this combination treatment.
What is the current status of trial NCT00370552?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2007-03. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00370552?
The interventions under investigation include: Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg (DRUG), Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg (DRUG), Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg (DRUG).
Who is sponsoring clinical trial NCT00370552?
This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00370552's enrollment target sits among peer trials
136 527th of 2000 higher than 1,469 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia